[Results of a phase I clinical trial of "theraphthal + ascorbic acid" catalytic system]. / Rezul'taty I fazy klinicheskogo izucheniia kataliticheskoi sistemy "teraftal + askorbinovaia kislota".
Vopr Onkol
; 47(6): 676-9, 2001.
Article
em Ru
| MEDLINE
| ID: mdl-11826487
ABSTRACT
Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Indóis
/
Antineoplásicos
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Ru
Ano de publicação:
2001
Tipo de documento:
Article